Hexarelin - Frequently Asked Questions
Part of the full Hexarelin guide - a growth-hormone-releasing peptide reference compound, identity-verified with a COA on every vial.
Straight answers
Hexarelin, answered
What class of peptide is hexarelin?
Per the entry, hexarelin is a growth-hormone-releasing peptide (GHRP) - specifically a synthetic hexapeptide studied as an agonist of the growth-hormone-secretagogue receptor 1a (GHS-R1a), the ghrelin receptor.
What is hexarelin's amino-acid sequence?
His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 - a six-residue peptide with a C-terminal amide (the '-NH2').
What receptor signaling pathway does the source describe for hexarelin?
In pituitary somatotroph models, GHS-R1a couples through Gq/11 to phospholipase C, generating IP3 and diacylglycerol, which mobilize intracellular calcium and engage protein kinase C. The entry notes this is mechanistically distinct from GHRH-receptor cAMP signaling.
Does hexarelin bind any receptor besides GHS-R1a?
Yes. The entry states hexarelin is also studied for binding the scavenger receptor CD36 in cardiovascular-tissue models, described strictly as in-vitro / ex-vivo receptor binding.
Why does hexarelin contain D-amino acids at positions 2 and 5?
The D-2-methyl-tryptophan at position 2 and the D-phenylalanine at position 5 are described as conferring resistance to enzymatic degradation and shaping receptor affinity.
What are hexarelin's molecular weight, formula, and CAS number?
Molecular weight 887.04 g/mol, molecular formula C47H58N12O6, and CAS Registry Number 140703-51-1, per the entry (MW attributed to ChemicalBook / Cayman).
What research areas are associated with hexarelin in the source?
Three: GHS-R1a agonist pharmacology (PLC/IP3/PKC/Ca signaling), comparative GHRP receptor-binding studies, and CD36 scavenger-receptor binding in cardiovascular-tissue models.
What primary citation does the entry provide?
Deghenghi, R., et al. (1994), 'GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats,' Life Sciences, PMID 7910650. No DOI is listed.
Does the entry give a half-life for hexarelin?
No. The entry provides no numeric half-life or PK value. It supplies only the qualitative structural note that the D-2-methyl-Trp(2) and D-Phe(5) substitutions resist enzymatic degradation; any storage guidance beyond that is general peptide-class principle, not hexarelin-specific data.
How is the molecular weight used in laboratory reconstitution?
For research handling, the 887.04 g/mol molecular weight converts a mass-per-volume stock into molarity (divide grams-per-liter by 887.04 to get mol/L). The chosen solvent volume sets the stock concentration; this is bench math for a reagent, not a dosing protocol.
How does hexarelin's signaling differ from GHRH-type peptides?
The entry contrasts hexarelin's GHS-R1a / Gq/11 / PLC / IP3 / PKC / calcium route with GHRH-receptor signaling, which works through cAMP - making the two mechanistically distinct receptor-pharmacology categories.
Is any human-use or therapeutic claim made for hexarelin in the entry?
No. The entry states all description is in-vitro and ex-vivo receptor pharmacology, with no therapeutic or human-use claim.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Hexarelin is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.